Concepedia

Alejandra Camino

AC

5

Publications

3.8K

Citations

5

H-Index

2007

Active since

Affiliations

Iuliu Hațieganu University of Medicine and Pharmacy(Current)

Baker Heart and Diabetes Institute

Semmelweis University

St. Michael's Hospital

University of Edinburgh

Alejandra Camino is an author at Iuliu Hațieganu University of Medicine and Pharmacy specializing in medicine, diabetes, and metabolic syndrome.

Top concepts

Publications per year

2007–2019

5

Publications

5

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

, , +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

, , +10

The pan‐caspase inhibitor Emricasan (<scp>IDN</scp>‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis

Fernando Javier Barreyro, Silvia Holod, Paola Finocchietto et al. · Liver International · 2014 · 280 citations · Full text

Adenovirus‐mediated inhibition of SPARC attenuates liver fibrosis in rats

Alejandra Camino, Catalina Atorrasagasti, Daniela R. Macció et al. · The Journal of Gene Medicine · 2008 · 59 citations

Trypanosoma cruzi: In vitro and in vivo antiproliferative effects of epigallocatechin gallate (EGCg)

María C. Güida, Mónica I. Esteva, Alejandra Camino et al. · Experimental Parasitology · 2007 · 39 citations

, , +5

Rows per page

1–5 of 5